Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.39 |
| ▸ | GABRD | O14764 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | GABRE | P78334 | 3/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8369041 | 0.85 | GABRR1 (0.40) | GABRR1LMNATSHRKMT2AGABBR2 | |
| SCHEMBL13175310 | 0.85 | TDP1 (0.41) | GABRR1LMNATSHRKMT2AGABBR2 | |
| SCHEMBL9823979 | 0.84 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6916433 | 0.82 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3153656 | 0.82 | TDP1 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3328215 | 0.79 | TDP1 (0.37) | GABRR1LMNATSHRKMT2ATDP1 | |
| SCHEMBL6048479 | 0.78 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Cadaverine Tartrate SCHEMBL29546907 | 0.76 | TET2 (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4541642 | 0.76 | ENPEP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11798905 | 0.75 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137592-A1 | PROCESS FOR PREPARING PURINE DERIVATIVE | AUROBINDO PHARMA LTD (IN) | 2010-06-03 | — | — | US | disclosed |
| EP-2170840-A1 | AN IMPROVED PROCESS FOR PREPARING PURINE DERIVATIVE | Aurobindo Pharma Ltd (IN) | 2010-04-07 | — | — | EP | disclosed |
| EP-1636231-B1 | METHODS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE USING A COMPOUND OF 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES | KYUNGDONG PHARM CO LTD (KR) | 2010-03-24 | — | — | EP | disclosed |
| EP-1551839-B1 | PROCESS FOR PREPARING 9-¬4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL -2-AMINOPURINE | KYUNGDONG PHARM CO LTD (KR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008155613-A1 | AN IMPROVED PROCESS FOR PREPARING PURINE DERIVATIVE | AUROBINDO PHARMA LTD (IN) | 2008-12-24 | — | — | WO | disclosed |
| US-7456282-B2 | 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same | KYUNGDONG PHARM. CO., LTD. (KR) | 2008-11-25 | — | — | US | disclosed |
| WO-2008072074-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PURINE DERIVATIVE | AUROBINDO PHARMA LIMITED (IN) | 2008-06-19 | — | — | WO | disclosed |
| US-20060258862-A1 | 2-Amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same | KYUNGDONG PHARM. CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| US-7041823-B2 | Process for preparing 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine | KYUNGDONG PHARM. CO., LTD. (KR) | 2006-05-09 | — | — | US | disclosed |
| EP-1636231-A2 | 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES AND PREPARING METHODS FOR 9- 4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]- 2- AMINOPURINE USING THE SAME | Kyungdong Pharm. Co., Ltd. (KR) | 2006-03-22 | — | — | EP | disclosed |
| US-20050222413-A1 | Process for preparing 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine | KYUNGDONG PHARM CO., LTD. (KR) | 2005-10-06 | — | — | US | disclosed |
| EP-1551839-A1 | PROCESS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE | Kyungdong Pharm. Co., Ltd. (KR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004110343-A2 | 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES AND PREPARING METHODS FOR 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]- 2- AMINOPURINE USING THE SAME | KYUNGDONG PHARM. CO., LTD. (KR) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004007497-A1 | PROCESS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE | KYUNGDONG PHARM. CO., LTD. (KR) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258862-A1 | 2-Amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same | TYMP, TPMT, PNP | GABRP 2796/4885GABRD 3373/4885GABRA1 2811/4885 |
| US-20100137592-A1 | PROCESS FOR PREPARING PURINE DERIVATIVE | TYMP, PNP, UMPS | GABRP 2636/4885GABRD 3445/4885GABRA1 3703/4885 |
| US-20050222413-A1 | Process for preparing 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine | TPMT, TYMP, MTAP | GABRP 1742/4885GABRD 2162/4885GABRA1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.